Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0378 • ACR Convergence 2020
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Joseph Merola¹, Peter Taylor², Andrew Bushmakin³, Joseph Cappelleri³, Pamela Young⁴, Rebecca Germino⁵ and Gil Yosipovitch⁶, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶University of Miami, Miami, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
Abstract Number: 0581 • ACR Convergence 2020
A Proposed Economic Framework to Model the Consequences of Psoriatic Arthritis Disease Domains
Jacquelyn Chou¹, Ervant Maksabedian², David Collier³ and Howard Thom⁴, ¹PRECISION heor, Los Angeles, CA, ²Amgen Inc., LOS ANGELES, CA, ³Amgen, Thousand Oaks, CA, ⁴University of Bristol, Bristol, England, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) manifests heterogeneous signs and symptoms (e.g., dactylitis, enthesitis, axial involvement, skin- and nail disease), which may respond to treatments differently. While…
Abstract Number: 0903 • ACR Convergence 2020
Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Arthritis: An Analysis of the OPAL Dataset
Sabina Ciciriello¹, Tegan Smith², Geoffrey Littlejohn³, Kathleen Tymms⁴, David Mathers⁵, Helen Cooley⁶, Hedley Griffiths⁷, Catherine OSullivan² and Peter Youssef⁸, ¹Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ⁴Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁵Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁶Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁷Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia, ⁸University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia
Background/Purpose: In Australia the cost of biologic/targeted synthetic DMARDs (b/tsDMARDs) for treatment of PsA is subsidized if the patient has documented high levels of clinical/laboratory…
Abstract Number: 1325 • ACR Convergence 2020
Monoclonal Gammopathy in Psoriatic Arthritis
Vanessa Ocampo¹ and Dafna Gladman², ¹University of Toronto, University Health Network, Psoriatic Arthritis Research Program, Toronto, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant clonal plasma disorder, defined by the presence of a serum monoclonal protein (M-protein) at…
Abstract Number: 1353 • ACR Convergence 2020
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
Laura Coates¹, Désirée van der Heijde², Lars Erik Kristensen³, William Tillett⁴, Jason Eells⁵, Tommi Nurminen⁶ and Atul Deodhar⁷, ¹University of Oxford, Oxford, United Kingdom, ²Leiden University Medical Center, Leiden, Netherlands, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Pre-existing structural damage in patients with psoriatic arthritis (PsA) has been suggested to impact therapeutic improvements in disease activity and functional outcomes.1,2 Here we…
Abstract Number: 1546 • ACR Convergence 2020
Ultrasound, Magnetic Resonance Imaging and Radiography of the Fingers’ Joints of Psoriatic Arthritis Patients
Ari Polachek¹, Victoria Furer², Mirna Zureik³, Sharon Nevo³, Liran Mendel⁴, David Levartovsky², Jonathan Wollman⁴, Valerie Aloush², Reut Tzemach⁴, Ofir Elalouf⁵, Marina Anouk⁶, Mark Berman², Ilana Kaufman⁷, Yael Lahat goldstein², Hagit Sarbagil-Maman⁸, Sara Borok Lev-Ran², Adi Broide³, Lihi Eder⁹, Daphna Paran², Moshe Iluz¹⁰, Iris Eshed¹¹ and Ori Elkayam³, ¹Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁴Souraaky Medical Center, Tel-Aviv, Israel, ⁵Souraaky Medical Center, Herzliya, Israel, ⁶Souraaky Medical Center, Tel Aviv, Israel, ⁷Tel Aviv Sourasky Medical Center, Petah-Tiqwa, Israel, ⁸Tel-Aviv Sourasky Medical Center, Kiryat Ono, Israel, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰Souraaky Medical Center, Tel-Aviv, ¹¹Sheba Medical Center, Tel-Aviv, Israel
Background/Purpose: Ultrasound (US), magnetic resonance imaging (MRI) and conventional radiography are the leading imaging modalities for musculoskeletal (MSK) assessment in PsA. However, little is reported…
Abstract Number: 2017 • ACR Convergence 2020
Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis
Philip Mease¹, Désirée van der Heijde², Bruce Kirkham³, Georg Schett⁴, Ana-Maria Orbai⁵, Christopher Ritchlin⁶, Joseph Merola⁷, Luminita Pricop⁸, Xuan Zhu⁹, DavidA James⁹ and Gregory Ligozio⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸Novartis Pharmaceuticals Corporation, East Hanover, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Assessment of radiographic joint damage extent and progression is important in clinical trials evaluating treatments for psoriatic arthritis (PsA). Joint damage in patients with…
Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Johan Dalén¹, Karin Luttropp¹, Tor Olofsson², Christopher Black³ and Amy Puenpatom⁴, ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ³Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
Abstract Number: 0316 • ACR Convergence 2020
High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis
Siba Raychaudhuri¹, Yasser Abdelhafez², Soumajyoti Sarkar³, Smriti Raychaudhuri⁴ and Abhijit Chaudhari², ¹Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ²University of California, Davis, Sacramento, CA, ³University of California, Davis, Davis, ⁴VA Sacramento Medical Center, Davis, CA
Background/Purpose: To validate high-sensitivity PET/CT as a diagnostic test we have explored the association of total-body and extremity PET/CT measures with the standardized psoriatic arthritis…
Abstract Number: 0332 • ACR Convergence 2020
Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Jeffrey R Curtis¹, Iain McInnes², Proton Rahman³, William Tillett⁴, Philip Mease⁵, Alexa Kollmeier⁶, Elizabeth Hsia⁷, Bei Zhou⁸, Prasheen Agarwal⁸, Steven Peterson⁹ and Chenglong Han⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁶Janssen Research & Development, LLC, La Jolla, CA, ⁷Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific MAb Guselkumab (GUS) in PsA patients, who experience impaired physical function, resulting in…
Abstract Number: 0352 • ACR Convergence 2020
Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results
Josef Smolen¹, Anthony Sebba², Eric Ruderman³, Amanda Gellett⁴, Christophe Sapin⁴, Aubrey Sprabery⁴, Soyi Liu-Leage⁴, Sreekumar Pillai⁴, Paulo Reis⁴ and Peter Nash⁵, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Arthritis Associates, Palm Harbor, Tampa, FL, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting IL-17A, was superior to adalimumab (ADA) at Week (Wk) 24 for simultaneous achievement of ACR50 and…
Abstract Number: 0379 • ACR Convergence 2020
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in DMARD-Naive Patients Treated with Apremilast
Philip Mease¹, Arthur Kavanaugh², Alexis Ogdie³, Alvin Wells⁴, Martin Bergman⁵, Dafna Gladman⁶, Sven Richter⁷, Michele Brunori⁸, Lichen Teng⁷, Benoit Guerette⁷ and Josef Smolen⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²UC San Diego Health System, San Diego, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Aurora Rheumatology and Immunotherapy Center, Franklin, ⁵Drexel University College of Medicine, Philadelphia, PA, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Amgen Inc., Thousand Oaks, ⁸Amgen Europe GmbH, Rotkreuz, Switzerland, ⁹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase III PALACE 4 (NCT01307423) assessed the efficacy of apremilast (APR) in DMARD-naive patients with PsA. The Routine Assessment of Patient Index Data 3…
Abstract Number: 0583 • ACR Convergence 2020
Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis
Santos Castañeda¹, Esther Francisca Vicente-Rabaneda², Mar Llamas-Velasco³, Javier Sánchez-Pérez³, José Pardo⁴, Rita Cabeza-Martínez⁵, Mercedes Miranda-Fontes⁶, Juan Márquez⁷, Jaime Calvo-Alén⁸, Susana Armesto⁹, Isabel Belinchón¹⁰, Alejandro Gómez¹¹, María Dolores Miranda¹², Silvia Martínez-Pardo¹³, Leticia Merino Melendez¹⁴, Miguel Ángel Casado¹⁵, María Yébenes¹⁵ and Araceli Casado¹⁵, ¹Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ²Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁴H.G.U. Santa Lucía, Cartagena, Murcia, Spain, ⁵H.U. Puerta de Hierro Majadahonda, Madrid, Madrid, Spain, ⁶H.U. Río Hortega, Valladolid, Valladolid, Castilla y Leon, Spain, ⁷H.G. Jerez de la Frontera, Cádiz, Andalucia, Spain, ⁸Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ⁹H.U. Marqués de Valdecilla, Santander, Cantabria, Spain, ¹⁰H.G.U. Alicante, Alicante, Comunidad Valenciana, Spain, ¹¹H.U. Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain, ¹²H.G. San Agustín de Linares, Jaen, Andalucia, Spain, ¹³H. Mutua de Terrassa, Barcelona, Catalonia, Spain, ¹⁴H. San Pedro, Logroño, Spain, ¹⁵Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Madrid, Spain
Background/Purpose: Psoriasis (Ps) and psoriatic arthritis (PsA) have a major impact on patients’ health-related quality of life. Cost of illness of patients with Ps, PsA and…
Abstract Number: 0905 • ACR Convergence 2020
Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis
Philip Mease¹, Arthur Kavanaugh², Alexis Ogdie³, Alvin Wells⁴, Martin Bergman⁵, Dafna Gladman⁶, Frank Behrens⁷, Sven Richter⁸, Michele Brunori⁹, Lichen Teng⁸, Benoit Guerette⁸ and Josef Smolen¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²UC San Diego Health System, San Diego, CA, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Aurora Rheumatology and Immunotherapy Center, Franklin, ⁵Drexel University College of Medicine, Philadelphia, PA, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸Amgen Inc., Thousand Oaks, ⁹Amgen Europe GmbH, Rotkreuz, Switzerland, ¹⁰Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Apremilast (APR) is associated with comparable ACR response rates in DMARD-naive vs DMARD-experienced patients (pts) with PsA (Wells AF, et al. Rheumatology. 2018;57:1253-63; Kavanaugh…
Abstract Number: 1328 • ACR Convergence 2020
Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and troponin I (TnI) are established cardiac biomarkers that predict cardiovascular events (CVEs) and mortality in apparently healthy individuals…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].